SG11202110828UA - Bicycle toxin conjugates and uses thereof - Google Patents
Bicycle toxin conjugates and uses thereofInfo
- Publication number
- SG11202110828UA SG11202110828UA SG11202110828UA SG11202110828UA SG11202110828UA SG 11202110828U A SG11202110828U A SG 11202110828UA SG 11202110828U A SG11202110828U A SG 11202110828UA SG 11202110828U A SG11202110828U A SG 11202110828UA SG 11202110828U A SG11202110828U A SG 11202110828UA
- Authority
- SG
- Singapore
- Prior art keywords
- bicycle
- toxin conjugates
- conjugates
- toxin
- bicycle toxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827899P | 2019-04-02 | 2019-04-02 | |
| US201962845954P | 2019-05-10 | 2019-05-10 | |
| US201962893835P | 2019-08-30 | 2019-08-30 | |
| PCT/GB2020/050874 WO2020201753A1 (en) | 2019-04-02 | 2020-04-02 | Bicycle toxin conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110828UA true SG11202110828UA (en) | 2021-10-28 |
Family
ID=70285719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110828UA SG11202110828UA (en) | 2019-04-02 | 2020-04-02 | Bicycle toxin conjugates and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220184222A1 (en) |
| EP (1) | EP3946462A1 (en) |
| JP (1) | JP2022528887A (en) |
| AU (1) | AU2020253990A1 (en) |
| CA (1) | CA3135569A1 (en) |
| IL (1) | IL286862A (en) |
| SG (1) | SG11202110828UA (en) |
| WO (1) | WO2020201753A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| US11261214B2 (en) | 2017-08-04 | 2022-03-01 | Bicycletx Limited | Bicyclic peptide ligand specific for CD137 |
| TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| JP7551500B2 (en) | 2018-04-04 | 2024-09-17 | バイスクルテクス・リミテッド | Heterotandem bicyclic peptide conjugates |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| EP3965827A1 (en) | 2019-05-09 | 2022-03-16 | BicycleTX Limited | Bicyclic peptide ligands specific for ox40 |
| TW202118770A (en) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
| EP4038096A1 (en) | 2019-10-03 | 2022-08-10 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| US20230233698A1 (en) * | 2020-06-12 | 2023-07-27 | Bicycletx Limited | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| AU2022328932A1 (en) * | 2021-08-17 | 2024-02-29 | Medshine Discovery Inc. | Polypeptide drug conjugate having novel structure and application thereof |
| CN118103075A (en) * | 2021-09-03 | 2024-05-28 | 拜斯科技术开发有限公司 | Synthesis of bicyclic peptide toxin conjugates and intermediates thereof |
| WO2024184661A1 (en) * | 2023-03-09 | 2024-09-12 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ518884A (en) | 1999-12-10 | 2004-02-27 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
| PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166718A0 (en) | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| KR101168441B1 (en) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| NZ555947A (en) | 2005-01-19 | 2010-11-26 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| DK2343320T3 (en) | 2005-03-25 | 2018-01-29 | Gitr Inc | ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF |
| PL2757099T3 (en) | 2005-05-12 | 2018-02-28 | Abbvie Bahamas Limited | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| BRPI0613361A2 (en) | 2005-07-01 | 2011-01-04 | Medarex Inc | isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| RS53627B1 (en) | 2005-10-07 | 2015-04-30 | Exelixis Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| PT2348023E (en) | 2005-12-13 | 2015-09-15 | Incyte Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| US7781433B2 (en) | 2006-04-26 | 2010-08-24 | Piramed Limited | Pharmaceutical compounds |
| PL2081435T3 (en) | 2006-09-22 | 2016-11-30 | Inhibitors of bruton's tyrosine kinase | |
| KR101737753B1 (en) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | Phenyl amino pyrimidine compounds and uses thereof |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
| AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| JP5570999B2 (en) | 2008-01-03 | 2014-08-13 | ユニベルシテ デ―マルセイユ | Composition for use in anti-HIV therapy |
| PT2257624E (en) | 2008-02-05 | 2012-05-29 | Medical Res Council | Methods and compositions |
| WO2009114512A1 (en) | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| SI4209510T1 (en) | 2008-12-09 | 2024-04-30 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| RU2646139C1 (en) | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Anti-gitr antibodies |
| DK2949670T3 (en) | 2009-12-10 | 2019-05-13 | Hoffmann La Roche | Antibodies that preferably bind human extracellular CSF1R domain 4 and use thereof |
| LT2542256T (en) | 2010-03-04 | 2019-10-25 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| MX2012010014A (en) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Antibodies against human csf-1r and uses thereof. |
| EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN112480256A (en) | 2010-05-04 | 2021-03-12 | 戊瑞治疗有限公司 | Antibodies that bind CSF1R |
| NZ714128A (en) | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
| MA34813B1 (en) | 2010-12-09 | 2014-01-02 | Univ Pennsylvania | USE OF CHIMERIC CHIMERIC RECEPTOR-MODIFIED T-CELLS FOR TREATING CANCER |
| NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| HUE051954T2 (en) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| AU2012374617B2 (en) | 2012-05-11 | 2015-09-17 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| US10624968B2 (en) * | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| TWI825046B (en) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
| GB201810316D0 (en) * | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
-
2020
- 2020-04-02 SG SG11202110828UA patent/SG11202110828UA/en unknown
- 2020-04-02 WO PCT/GB2020/050874 patent/WO2020201753A1/en active Application Filing
- 2020-04-02 US US17/594,031 patent/US20220184222A1/en not_active Abandoned
- 2020-04-02 JP JP2021558958A patent/JP2022528887A/en active Pending
- 2020-04-02 AU AU2020253990A patent/AU2020253990A1/en not_active Abandoned
- 2020-04-02 CA CA3135569A patent/CA3135569A1/en active Pending
- 2020-04-02 EP EP20718739.4A patent/EP3946462A1/en not_active Withdrawn
-
2021
- 2021-09-30 IL IL286862A patent/IL286862A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3946462A1 (en) | 2022-02-09 |
| AU2020253990A1 (en) | 2021-10-28 |
| WO2020201753A1 (en) | 2020-10-08 |
| JP2022528887A (en) | 2022-06-16 |
| US20220184222A1 (en) | 2022-06-16 |
| CA3135569A1 (en) | 2020-10-08 |
| IL286862A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286862A (en) | Bicycle toxin conjugates and uses thereof | |
| IL286291A (en) | Compounds and conjugates thereof | |
| IL268102A (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| EP3626825A4 (en) | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate | |
| IL287391A (en) | Amatoxin antibody-drug conjugates and uses thereof | |
| IL278877B1 (en) | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof | |
| IL284974A (en) | Anti-cd228 antibodies and antibody-drug conjugates | |
| ZA202002207B (en) | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof | |
| IL286847A (en) | Hsp90-binding conjugates and formulations thereof | |
| SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
| EP3645041A4 (en) | Anti-mertk agonistic antibody-drug conjugates and uses thereof | |
| IL277791A (en) | Hsp90-targeting conjugates and formulations thereof | |
| IL266112A (en) | Anti-edb antibodies and antibody-drug conjugates | |
| SG11202106067UA (en) | Tubulysins and protein-tubulysin conjugates | |
| EP3638306A4 (en) | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof | |
| IL291312A (en) | Anti-ptcra antibody-drug conjugates and uses thereof | |
| SG11202011232VA (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| IL287917A (en) | Hyaluronan conjugates and uses thereof | |
| GB201902182D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| GB201820864D0 (en) | Antibody-drug conjugates | |
| GB201806022D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| EP3856258C0 (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| GB201903535D0 (en) | Compounds and conjugates | |
| GB201903541D0 (en) | Compounds and conjugates | |
| GB201818562D0 (en) | Pyrrolobenzodiazephones and conjugates thereof |